Dimension Therapeutics, Inc. (NASDAQ:DMTX) is at an overbought level with an RSI(14) at 90.72.
The Relative Strength Index (RSI) is one of the most widely used technical indicators used to evaluate strengthening and weakening momentum in price action. RSI levels 70 and above are considered overbought with RSI’s under 30 indicating oversold. Overbought is a condition that occurs when prices are considered too high and may be susceptible to a decline.
The stock’s Average True Range (ATR) is sitting at 0.34. The ATR is a short term indicator of volatility. It can’t tell you the direction of the stock but indicates how likely the price is to change.
Shares are trading at $5.88 significantly higher than the 50 day moving average which is $2.55 and which is well above the 200 day moving average of $1.73. The 50 day moving average moved up $3.33 and the 200 day average moved up $4.15.
Dimension Therapeutics, Inc. in the news.
Traders are more bearish on shares of the company of late if you take note of the rise in short interest. The stock had a rise in short interest of 43.23% as of August 31, 2017 from the last reporting period. Short shares increased from 167,306 to 239,632 over that period. With short interest at 239,632 and short average daily volume at 494,269, days to cover is 0.0 and the short interest percentage is 0.01% as of August 31.
Recent Analyst Ratings
On September 19 the company was rated “Sell” by Citigroup which is down from the previous “Neutral” rating. On August 30, 2017 the stock rating was set at “Hold” in a report from Canaccord Genuity a cut from the previous “Buy” rating.
In the last earnings report the EPS was $-2.13 and is estimated to be $-2.10 for the current year with 25,052,000 shares now outstanding. Next quarter’s EPS is expected be $-0.56 with next year’s EPS anticipated to be $-1.72.
Dimension Therapeutics, Inc., launched on June 20, 2013, is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The Company has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Business’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. The Company uses mammalian cells in its manufacturing approach for its AAV-based product candidates. Its AAV manufacturing is performed in over two mammalian cell types, human embryonic kidney 293 cells (HEK293 cells) and HeLa cells..